君实生物 · Junshi Biosciences

Science

Pipeline Overview

Explore the 19 medicines in Junshi’s English pipeline chart, with additional records for selected clinical studies and U.S. authorization.

Sources reviewed 16 November 2026. Corporate stages group development by medicine. Registered studies and authorizations identify a specific indication or treatment setting.

Pipeline Chart

JS212EGFR × HER3 ADC TumorsCorporate program Phase I/II

Oncology · Junshi’s corporate chart places JS212 in the Phase I/II group. This grouping covers early clinical development.

View source
JS213PD-1 × IL-2 Advanced malignant tumorsCorporate program Phase I/II

Oncology · Junshi’s corporate chart places JS213 in the Phase I/II group. This grouping covers early clinical development.

View source
JS111EGFR exon 20 Non-small cell lung cancerCorporate program Phase I/II

Oncology · Junshi’s corporate chart places JS111 in the Phase I/II group. This grouping covers early clinical development.

View source
JS214VEGF × TGF-β TumorsCorporate program Phase I/II

Oncology · Junshi’s corporate chart places JS214 in the Phase I/II group. This grouping covers early clinical development.

View source
JS110XPO1 Endometrial cancerCorporate program Phase I/II

Oncology · Junshi’s corporate chart places JS110 in the Phase I/II group. This grouping covers early clinical development.

View source
JS015DKK1 TumorsCorporate program Phase I/II

Oncology · Junshi’s corporate chart places JS015 in the Phase I/II group. This grouping covers early clinical development.

View source
JT002Small nucleic acid immunomodulator Seasonal allergic rhinitisCorporate program Phase I/II

Autoimmune · Junshi’s corporate chart places JT002 in the Phase I/II group. This grouping covers early clinical development.

View source
JS207PD-1 × VEGF TumorsCorporate program Phase III

Oncology · Junshi’s corporate chart places JS207 in the Phase III group.

View source
JS203CD20 × CD3 TumorsCorporate program Phase III

Oncology · Junshi’s corporate chart places JS203 in the Phase III group.

View source
JS007CTLA-4 Lung cancer and melanomaCorporate program Phase III

Oncology · Junshi’s corporate chart places JS007 in the Phase III group.

View source
TifcemalimabBTLA Lung cancer and lymphomaCorporate program Phase III

Oncology · Junshi’s corporate chart places Tifcemalimab in the Phase III group.

View source
RoconkibartIL-17A Psoriasis and spondylitisCorporate program Phase III

Autoimmune · Junshi’s corporate chart places Roconkibart in the Phase III group.

View source
JS001scPD-1 TumorsCorporate program Phase III

Oncology · Junshi’s corporate chart places JS001sc in the Phase III group.

View source
JS105PI3K-α Gynecological tumorsCorporate program Phase III

Oncology · Junshi’s corporate chart places JS105 in the Phase III group.

View source
JS107Claudin 18.2 ADC Gastrointestinal cancerCorporate program Phase III

Oncology · Junshi’s corporate chart places JS107 in the Phase III group.

View source
ToripalimabPD-1 Oncology indicationsCorporate program Marketed

Oncology · Junshi includes Toripalimab in the marketed group. Approved indications vary by jurisdiction.

View source
AdalimumabTNF-α Rheumatoid arthritis and other approved indicationsCorporate program Marketed

Autoimmune · Junshi includes Adalimumab in the marketed group. Approved indications vary by jurisdiction.

View source
Deuremidevir hydrobromide (VV116)RdRp COVID-19Corporate program Marketed

Infectious diseases · Junshi includes Deuremidevir hydrobromide (VV116) in the marketed group. Approved indications vary by jurisdiction.

View source
OngericimabPCSK9 Primary hypercholesterolemia and mixed dyslipidemiaCorporate program Marketed

Metabolic · Junshi includes Ongericimab in the marketed group. Approved indications vary by jurisdiction.

View source
JS212EGFR × HER3 ADC Recurrent or metastatic triple-negative breast cancerRegistered study Phase II

Oncology · JS212 alone or in combination is being studied in a Phase II trial.

View source
JS212EGFR × HER3 ADC Advanced malignant solid tumorsRegistered study Phase I/II

Oncology · An early-phase study evaluates JS212 in participants with advanced malignant solid tumors.

View source
JS203CD20 × CD3 Relapsed or refractory diffuse large B-cell lymphomaRegistered study Phase III

Oncology · This Phase III study compares JS203 plus chemotherapy with rituximab plus chemotherapy.

View source
TifcemalimabBTLA Limited-stage small-cell lung cancerRegistered study Phase III

Oncology · A Phase III study evaluates consolidation treatment with toripalimab alone or with tifcemalimab after chemoradiotherapy.

View source
Toripalimab-tpziPD-1 Nasopharyngeal carcinomaU.S. authorization Approved

Oncology · The U.S. FDA approved toripalimab-tpzi for defined adult nasopharyngeal carcinoma indications, both in combination with chemotherapy and as a single agent in specified settings.

View source

Program Details

The company’s product directory lists 37 additional entries across four therapeutic areas. The English stage chart does not assign these entries a phase.

Oncology (29)
  • JS211
  • JS209
  • JS208
  • JS206
  • JS205
  • JS123
  • JS122
  • JS121
  • JS120
  • JS115
  • JS114
  • JS104
  • JS018
  • JS013
  • JS011
  • JS201
  • JS125
  • JS116
  • JS113
  • JS112
  • JS108
  • JS101
  • JS019
  • JS014
  • JS012
  • JS009 (TAB009)
  • JS006 (TAB006)
  • JS003
  • Bevacizumab (JS501)
Autoimmune (1)
  • UBP1213sc
Metabolic (3)
  • JS008
  • JS401
  • JS103
Infectious diseases (4)
  • JT109
  • JT003 (VV993)
  • JS026
  • Etesevimab

Bevacizumab (JS501), a VEGF-targeted program, appears in the oncology directory. The company reported Phase III on 28 March 2024. See the dated investor disclosure

Open the company’s product directory